Progress in diagnosis and treatment of diabetic retinopathy

Barbara Mirkiewicz-Sieradzka

Review article

PDF

Ocena bezpieczeństwa i skuteczności stosowania preparatu AVANDIA (rosiglitazon) w leczeniu cukrzycy typu 2 - program ROSE

Jacek Sieradzki, Przemysław Witek, Teresa Koblik, Paweł Kapuściński, Jacek Cybulski, grupa badaczy ROSE

Research paper

PDF

The PolDiab Study. Part I. Analysis of diabetes treatment in Poland

Jacek Sieradzki, Władysław Grzeszczak, Waldemar Karnafel, Bogna Wierusz-Wysocka, Adam Manikowski, Tomasz Szymońsk

Research paper

PDF

Muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell fuction in db/db mice

Thomas Harrity, Dennis Farrelly, Aaron Tieman, Cuixia Chu, Lori Kunselman, Liqun Gu, Randolph Ponticiello, Michael Cap, Fucheng Qu, Chunning Shao, Wei Wang, Hao Zhang, William Fenderson, Sean Chen, Pratik Devasthale, Yoon Jeon, Ramakrishna Seethala, Wen-Pin Yang, Jimmy Ren, Min Zhou, Denis Ryono, Scott Biller, Kasim A. Mookhtiar, John Wetterau, Richard Gregg, Peter T. Cheng, Narayanan Hariharan

Other materials agreed with the Editors

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

The Diabetes Prevention Program Research Group

Other materials agreed with the Editors

Effects of sustained insulin-induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes

Minna L. Koivikko, Pasi I. Salmela, K.E. Juhani Airaksinen, Juha S. Tapanainen, Aimo Ruokonen, Timo H. Mäkikallio, Heikki V. Huikuri

Other materials agreed with the Editors

Postprandial hyperglycemia and diabetes complications. Is it time to treat?

Antonio Ceriello

Other materials agreed with the Editors